St Gallen Breast Cancer Conference 2023. Day 2

Updates in HER2+ breast cancer: adjuvant therapies, early-stage data, and tumour heterogeneity

HER2 status has important implications for treatment selection and sequencing in early stages of breast cancer. While treatments targeting HER2 are the standard for managing HER2+ BC, trials exploring related targets are showing promising initial results.

#breastcancer #clinicaltrials

https://www.medthority.com/medical-education/st-gallens-2023-congress-highlights/st.-gallen-international-breast-cancer-conference-2023-day-2/